Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Perspective Therapeutics, Inc.

NYSE: CATX · Life Sciences · 14 alerts · CIK 728387

Perspective Therapeutics, Inc. stories on ALFA USA NewsRead the news →
Share price
$0.9238Close, Nov 16
Market cap
$112M
Shares outstanding
120.76MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Perspective Therapeutics, Inc. filings on SEC EDGAR ↗

6:20 AM ET 8-K
Research Collaboration

Perspective Therapeutics Research Collaboration with Merck

Perspective Therapeutics has entered into a clinical trial collaboration and supply agreement with Merck to evaluate its targeted alpha-particle therapy [212Pb]PSV359 in combination with Keytruda. The combination will be tested in an ongoing Phase 1/2a study for FAP-alpha positive solid tumors, with Perspective sponsoring the study and Merck providing pembrolizumab at no cost.

Counterparty
Merck

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.